Coverage: The Meridian legal market record (editorial).
A voluntary licence granted to an African manufacturer covering all 129 licensed countries, including every African country; African by licensee domicile and by licensed territory.
| Record ID | TX-AFR-2026-0069 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | In-licensing, Non-exclusive licence, Technology transfer |
| IP rights | patent, regulatory data, know-how |
| Status | Signed |
| Qualifying date | 2026-07-24 |
| Sector | Life sciences · HIV prevention (antiretrovirals) |
| African markets | South Africa, Kenya, Nigeria, Egypt |
| Licensed territory | 129 low- and lower-middle-income countries, including every African country. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Two or more independent secondary sources · 3 source(s) |
| Last verified | 2026-10-25 |
Parties
- Merck & Co. (MSD) (United States): licensor
- UCL (Kenya): licensee, manufacturer
Key terms
- Interest: non-exclusive royalty-free voluntary licence; Exclusivity: non-exclusive; Territorial scope: 129 low- and lower-middle-income countries including all of Africa; Term: Royalty-free; term not stated in the sources reviewed
- Financial terms as reported: “royalty-free agreements”
Sources
- Aspen gets Merck licensing agreement to make lower-cost HIV pill, BusinessDay (Reuters), 2026-07-24
- Aspen signs voluntary HIV prevention pill licensing agreement with MSD, CNBC Africa, 2026-07-24
- AIDS 2026: some pieces falling into place for monthly HIV prevention pill, but key data not yet in, allAfrica, 2026-07-29
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


